Sanofi’s R&D plans, despite being noteworthy, couldn’t convince investors
07/12/23 -"Sanofi has unveiled its R&D plans today in an effort to convince investors of their effectiveness, as the share price hasn’t yet fully recovered after collapsing c.20% in October 2023 following ..."
Pages
73
Language
English
Published on
07/12/23
You may also be interested by these reports :
07/05/25
Q1 profits exceeded the street’s expectations. Nonetheless, 2025 guidance was downgraded owing to competition from compounded drugs, which, however, ...
06/05/25
1:10 share split adjustments – Downgrade to Add (prev.: Buy)
06/05/25
Q1 results met expectations, and strong growth was witnessed across the segments as well as three key molecules. Of note was a rebound in the animal ...
05/05/25
BioNTech’s narrative is straightforward: the company develops drugs for life-threatening illnesses and generated significant revenue by developing ...